A phase 1b, multi-center, open-label dose escalation and expansion platform study of VAY736 as single agent and in combination with select antineoplastic agents in patients with non-Hodgkin Lymphoma (NHL)

  • Wong, Shu (Primary Chief Investigator (PCI))
  • Kennedy, Nola (Project Manager)

Project: Research

Project Details

Project Description

Animal Ethics: Not required; Human Ethics: N/A (Ethics remains through Alfred as per head agreement); Gene Tech: Not required; Biosafety/Radiation: No; Split Grants: N/A
Effective start/end date9/11/2131/12/26


  • Malignant Haematology
  • Non-hodgkin lymphoma
  • Clinical trial